{"domain":"annovisbio.com","status":"valid","tier":"listed","authority":47,"verified":false,"title":"Annovis Bio, Inc. (NYSE: ANVS)","summary":"Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targetin","country":"US","country_source":"ip","llms_txt":"https://www.annovisbio.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-21T11:40:58.414Z","agent_terms":null,"categories":["healthcare","science-research"],"capabilities":[],"inferred_tags":["buntanetap","alzheimers disease","parkinsons disease","clinical trials","neurodegeneration"],"audience":"mixed","agent_uses":["search_content"],"language":"en","platform_generated":false,"agent_summary":"Annovis Bio (NYSE: ANVS) clinical-stage biotech developing buntanetap for Alzheimer's and Parkinson's; covers pipeline, Phase 3 trials and patents.","llms_txt_cached":"https://agentwebmap.com/v1/domain/annovisbio.com/llms.txt","agentic":"informational","section_keys":["clinical-trials","company","contact","news-and-investors"],"section_partial":false,"section_indexed_at":"2026-10-21T14:25:35.652Z"}